drugset / Trial / NCT01018810
A Study for Adults With Plaque Psoriasis
RandomizedParallel-groupTriple-blindTreatment
Summary
In this study, we will evaluate clinical activity, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of 5 LY2525623 dosing groups compared to placebo in adults with plaque psoriasis.
Timeline
- Start
- 2009-12
- Primary completion
- 2010-05
- Completion
- 2010-08
Outcome
Outcome not reported
Stopped: “The trial was terminated for several reasons, including complexities in development of LY2525623, but not because of safety concerns”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY2525623 | Unknown | 3 mg | Intravenous |
| Subject | LY2525623 | Unknown | 10 mg | Intravenous |
| Subject | LY2525623 | Unknown | 30 mg | Intravenous |
| Subject | LY2525623 | Unknown | 90 mg | Intravenous |
| Subject | LY2525623 | Unknown | 180 mg | Intravenous |